Evidence map›Paper›PMID 27812924›Full record

ReviewMolecular imaging and biology2017

High-Throughput Approaches to the Development of Molecular Imaging Agents.

Lina Y Hu, Kimberly A Kelly, Julie L Sutcliffe

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular imaging and biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Translating a radiolabeled imaging agent to the clinic.Advanced drug delivery reviews · 2022
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lina Y HuDepartment of Biomedical Engineering, University of California Davis, Davis, CA, USA.
Kimberly A KellyDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.
Julie L SutcliffeDepartment of Biomedical Engineering, University of California Davis, Davis, CA, USA. jlsutcliffe@ucdavis.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Dina Gould Halme · 1987 to 2026
$72.1M
Development of Molecularly Targeted Imaging Agents for Early Detection of PDACR01CA137071 · NCI · UNIVERSITY OF VIRGINIA · PI KELLY, KIMBERLY A. · 2008 to 2012
$1.3M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA137071
6 · The paper itself

Abstract

Molecular imaging allows for the visualization of changes at the cellular level in diseases such as cancer. A successful molecular imaging agent must rely on disease-selective targets and ligands that specifically interact with those targets. Unfortunately, the translation of novel target-specific ligands into the clinic has been frustratingly slow with limitations including the complex design and screening approaches for ligand identification, as well as their subsequent optimization into useful imaging agents. This review focuses on combinatorial library approaches towards addressing these two challenges, with particular focus on phage display and one-bead one-compound (OBOC) libraries. Both of these peptide-based techniques have proven successful in identifying new ligands for cancer-specific targets and some of the success stories will be highlighted. New developments in screening methodology and sequencing technology have pushed the bounds of phage display and OBOC even further, allowing for even faster and more robust discovery of novel ligands. The combination of multiple high-throughput technologies will not only allow for more accurate identification, but also faster affinity maturation, while overall streamlining the process of translating novel ligands into clinical imaging agents.

Indexed as

Amino Acid SequenceAnimalsCombinatorial Chemistry TechniquesHigh-Throughput Screening AssaysHumansIndicators and ReagentsMolecular ImagingPeptide LibraryPeptidesIndicators and ReagentsPeptide LibraryPeptidesCombinatorial libraryHigh-throughputMolecular imagingOBOCPeptidesPetPhage display

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.